Tagged with MorphoSys

Germany: Bayer’s Shares Reach Record Low; Halozyme Withdraws Bid for Evotec

Germany Germany: Bayer’s Shares Reach Record Low; Halozyme Withdraws Bid for Evotec

Germany A roundup of the biggest stories coming out of Germany’s pharma industry, including Bayer’s biggest share price drop in 20 years; Fresenius Kabi’s biosimilar deal with SamChunDang Pharm; Halozyme Therapeutics’ withdrawal from purchase of Evotec; Merck KGaA-controlled MilliporeSigma’s acquisition of HUB Organoids, and Gilead’s USD 465 million solid tumour deal…

Germany Pharma News: Germany Legalises Cannabis; Boehringer Ingelheim Weight-loss Candidate Shows MASH Potential

Germany Germany Pharma News: Germany Legalises Cannabis; Boehringer Ingelheim Weight-loss Candidate Shows MASH Potential

Germany The biggest pharma industry and healthcare stories from Germany, including the country’s legalisation of cannabis; the MASH potential of Boehringer Ingelheim’s obesity candidate; Bayer’s further share price drop and expansion into the US; the antibody-drug conjugate (ADC) specialist Tubulis’ series B2 financing, and Novartis’ deal with biotech MorphoSys. Germany’s…

European Biotech Roundup: BioNTech & CureVac Deal to Boost German Vaccine Capacity; Valneva’s Scottish Manufacturing Plans; Morphosys Consolidates German R&D

Europe European Biotech Roundup: BioNTech & CureVac Deal to Boost German Vaccine Capacity; Valneva’s Scottish Manufacturing Plans; Morphosys Consolidates German R&D

Europe A roundup of the latest news from European biotech, including BioNTech and CureVac’s German vaccine manufacturing deal; the revival of Valneva’s plans to manufacture its vaccine in Scotland; and Morphosys’ shuttering of its US R&D footprint. BioNTech, CureVac part of $3.14B deal to bolster German vaccine capacity through 2029:…